Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Durata Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01431339
First received: September 8, 2011
Last updated: December 27, 2013
Last verified: December 2013
  Purpose

The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.


Condition Intervention Phase
Abscess
Wound Infection
Surgical Site Infection
Cellulitis
Drug: IV Dalbavancin
Drug: Vancomycin/Linezolid
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Resource links provided by NLM:


Further study details as provided by Durata Therapeutics, Inc.:

Primary Outcome Measures:
  • Early Clinical Efficacy [ Time Frame: After 48-72 hours of therapy ] [ Designated as safety issue: No ]
    Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature


Secondary Outcome Measures:
  • Clinical Status [ Time Frame: End of Treatment Visit (Day 14-15) ] [ Designated as safety issue: No ]
    Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of other therapy

  • >= 20% Reduction in Lesion Area [ Time Frame: 48-72 hours after the initiation of study therapy ] [ Designated as safety issue: No ]
    Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size

  • Clinical Status [ Time Frame: Follow-Up Visit (day 28) ] [ Designated as safety issue: No ]
    Compare the clinical efficacy at the short term follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs temperature and receipt of other therapy


Enrollment: 739
Study Start Date: July 2011
Study Completion Date: December 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Vancomycin with possible switch to oral linezolid Drug: Vancomycin/Linezolid
IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
Experimental: Dalbavancin Drug: IV Dalbavancin
IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients 18 - 85 years of age.
  2. Signed and dated informed consent document.
  3. Major abscess, surgical site infection, traumatic wound infection or cellulitis suspected or confirmed to be caused by Gram-positive bacteria.
  4. At least two (2) local signs and symptoms of ABSSSI and at least one (1) systemic sign of infection.
  5. Requires a minimum of 3 days of IV therapy.
  6. Patient willing and able to comply with study procedures.

Exclusion Criteria:

Patients presenting with any of the following:

  1. A contra-indication to any required study drug.
  2. Pregnant or nursing females.
  3. Sustained shock.
  4. Participation in another study of an investigational drug or device within 30 days.
  5. Receipt of a systemically or topically administered antibiotic within 14 days prior to randomization, except receipt of a single dose of a short-acting antibacterial drug 3 or more days prior to randomization.
  6. Infection due to a dalbavancin or vancomycin-resistant organism.
  7. Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis, and/or endovascular infection.
  8. Exclusively gram-negative bacterial or a fungal ABSSSI.
  9. Venous catheter infection.
  10. Infection of a diabetic foot ulcer or a decubitus ulcer.
  11. Device-related infections.
  12. Gram-negative bacteremia.
  13. Infected burns.
  14. Infected limb with critical ischemia.
  15. Superficial/simple skin and skin structure infections.
  16. Concomitant condition requiring non-study antibacterial therapy.
  17. ABSSSI requiring therapy for longer than 14 days.
  18. Adjunctive therapy with hyperbaric oxygen.
  19. More than 2 surgical interventions for ABSSSI anticipated.
  20. Chronic inflammatory condition precluding assessment of clinical response.
  21. Absolute neutrophil count < 500 cells/mm3.
  22. Human immunodeficiency virus (HIV) infection with a CD4 cell count < 200 cells/mm3.
  23. Recent bone marrow transplant, > 20 mg prednisolone per day (or equivalent) or receiving immunosuppressant drugs after organ transplantation.
  24. Regular, chronic antipyretic use in patients unable to modify during the first three days of study drug therapy.
  25. Life expectancy less than 3 months.
  26. Conditions that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.
  27. Prior participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01431339

  Hide Study Locations
Locations
United States, Alabama
Durata Clinical Site
Montgomery, Alabama, United States, 36106
United States, California
Durata Clinical Site
Anaheim, California, United States, 92804
Durata Clinical Site
Buena Park, California, United States, 90620
Durata Study Site
Chula Vista, California, United States, 91911
Durata Clinical Site
Long Beach, California, United States, 90813
Durata Study Site
Los Angeles, California, United States, 90015
Durata Study Site
Norwalk, California, United States, 90650
Durata Study Site
Oxnard, California, United States, 93030
Durata Study SIte
San Diego, California, United States, 92120
Durata Study Site
Stockton, California, United States, 95204
United States, Florida
Durata Clinical Site
Boyton Beach, Florida, United States, 33435
Durata Clinical Site
Ft. Meyers, Florida, United States, 33966
Durata Clinical Site
Miami, Florida, United States, 33015
Durata Study Site
Orlando, Florida, United States, 32837
Durata Clinical Site
St. Cloud, Florida, United States, 34769
United States, Georgia
Durata Clinical Site
Augusta, Georgia, United States, 30901
Durata Study Site
Columbus, Georgia, United States, 31904
United States, Illinois
Durata Clinical Site
Chicago, Illinois, United States, 60637
United States, Louisiana
Durata Study Site
Baton Rouge, Louisiana, United States, 70809
Durata Study Site
New Orleans, Louisiana, United States, 70112
Durata Study Site
Shreveport, Louisiana, United States, 71101
Durata Study Site
Zachary, Louisiana, United States, 70791
United States, Nevada
Durata Study Site
Las Vegas, Nevada, United States, 89109
United States, Ohio
Durata Study Site
Springfield, Ohio, United States, 45502
United States, Pennsylvania
Durata Study Site
Philadelphia, Pennsylvania, United States, 19103
United States, Texas
Durata Clinical Site
Austin, Texas, United States, 78752
Durata Study Site
Austin, Texas, United States, 78701
Durata Clinical Site
Houston, Texas, United States, 77055
Durata Study Site
Richmond, Texas, United States, 77469
United States, Wisconsin
Durata Study Site
Middleton, Wisconsin, United States, 53562
Bulgaria
Durata Study Site
Pleven, Bulgaria, 5800
Durata Study Site
Plovdiv, Bulgaria, 4000
Durata Study Site
Sevlievo, Bulgaria, 5400
Durata Study Site
Sofia, Bulgaria, 1606
Durata Study Site
Sofia, Bulgaria, 1431
Durata Study Site
Sofia, Bulgaria, 1407
Durata Study Site
Sofia, Bulgaria, 1000
Estonia
Durata Clinical Site
Kohtla-Jarve, Estonia
Durata Study Site
Kohtla-Jarve, Estonia, 30322
Durata Clinical Site
Tallinn, Estonia, 10136
Durata Clinical Site
Tallinn, Estonia, 13419
Durata Study Site
Tartu, Estonia, 51014
Hungary
Durata Clinical Site
Budapest, Hungary
Durata Study Site
Budapest, Hungary, H-1081
Durata Study Site
Debrecen, Hungary, H-4043
Durata Clinical Site
Kaposvar, Hungary, H-7400
Durata Clinical SIte
Pecs, Hungary, H-7624
Durata Clinical Site
Szeged, Hungary, H-6720
Durata Study Site
Veszprem, Hungary, H-8200
Israel
Durata Clinical Site
Haifa, Israel, 31906
Durata Study Site
Jerusalem, Israel, 91120
Durata Clinical Site
Kfar Saba, Israel, 44281
Durata Study Site
Petach Tikva, Israel, 49100
Durata Clinical Site
Petah-Tiqva, Israel, 49100
Durata Clinical Site
Ramat-Gan, Israel, 52621
Durata Study Site
Tel Aviv, Israel, 64239
Korea, Republic of
Durata Clinical Site
Jung Gu, Daegu, Korea, Republic of, 700-721
Durata Clinical Site
Ansan, Korea, Republic of, 425-707
Durata Study Site
Daejeon, Korea, Republic of, 301721
Durata Study Site
Gwangju, Korea, Republic of, 501-757
Durata Clinical Site
Incheon, Korea, Republic of, 405-760
Durata Clinical Site
Kangwon-do, Korea, Republic of, 220-71
Durata Clinical Site
Seoul, Korea, Republic of, 136-705
Durata Clinical Site
Seoul, Korea, Republic of, 134-701
Durata Clinical Site
Seoul, Korea, Republic of, 152-703
Durata Study Site
Seoul, Korea, Republic of, 138-736
Durata Study Site
Seoul, Korea, Republic of, 135-710
Durata Study Site
Seoul, Korea, Republic of, 134-701
Durata Study Site
Seoul, Korea, Republic of, 133-791
Latvia
Durata Clinical Site
Daugavpils, Latvia, LV-5417
Durata Clinical Site
Liepaja, Latvia, LV-3414
Durata Study Site
Rezekne, Latvia, LV-4600
Durata Clinical Site
Riga, Latvia, LV-1002
Durata Study Site
Riga, Latvia, LV-1001
Durata Clinical Site
Ventspils, Latvia, LV-3601
Lithuania
Durata Clinical Site
Kaunas, Lithuania, LT-45130
Durata Clinical Site
Kauno m. sav, Lithuania, LT-47144
Durata Clinical Site
Klaipėda, Lithuania, LT-76231
Durata Clinical Trial
Vilnius, Lithuania, LT-10207
Durata Clinical Site
Šiauliai, Lithuania, LT-76231
Romania
Durata Clinical Trial
Bucharest, Romania, 042122
Durata Clinical Site
Bucharest, Romania, 010825
Durata Study Site
Bucharest, Romania, 75622
Durata Study Site
Bucharest, Romania, 010713
Durata Study Site
Bucharest, Romania, 011461
Durata Clinical Site
Burcharest, Romania, 020125
Durata Study Site
Cluj-Napoca, Romania, 400006
Durata Study Site
Constanta, Romania, 900709
Durata Study Site
Targu Mures, Romania, 540072
Durata Clinical Site
Timisoara, Romania, 300736
Russian Federation
Durata Clinical Site
Vsevolozhsk, Leningrad Region, Russian Federation, 188640
Durata Study Site
Vsevolozhsk, Leningrad, Russian Federation, 188864
Durata Clinical Site
Moscow, Russian Federation, 115280
Durata Study Site
Moscow, Russian Federation, 111539
Durata Study Site
Petrozavodsk, Russian Federation, 18519
Durata Clinical Site
Smolensk, Russian Federation, 214018
Durata Clinical Site
St. Petersburg, Russian Federation, 198099
Durata Study Site
Tomsk, Russian Federation
Durata Clinical Site
Tver, Russian Federation, 170036
Durata Clinical Site
Volgograd, Russian Federation, 400138
Durata Clinical Site
Yaroslavl, Russian Federation, 150003
Slovakia
Durata Clinical Site
Banska Bystrica, Slovakia, 975 17
Durata Clinical Site
Levice, Slovakia, 934 01
Durata Clinical Site
Nitra, Slovakia, 950 01
Durata Clinical Site
Svidnik, Slovakia, 089 01
South Africa
Durata Study Site
KwaZulu, Durban, South Africa, 4037
Durata Study Site
KwaZulu-Natal, Ladysmieth, South Africa, 3370
Durata Study Site
Mpumalanga, Middleburg, South Africa, 1055
Durata Study Site
Mpekweni, Paarl, South Africa, 7646
Durata Study Site
Western Cape, Paarl, South Africa, 7646
Durata Clinical Site
Gauteng, Pretoria, South Africa, 0001
Durata Study Site
Gauteng, Soweto, South Africa, 2013
Durata Study Site
Johannesburg, South Africa, 1500
Durata Study Site
Port Elizabeth, South Africa, 6014
Durata Study Site
Port Elizabeth, South Africa, 6070
Durata Clinical Site
Pretoria, South Africa, 0084
Durata Study Site
Thabazimbi, South Africa, 0380
Taiwan
Durata Study Site
Tainan, Fukien, Taiwan, 70403
Durata Study Site
Kaohsiung, Taiwan, 813
Durata Study Site
Kaohsiung, Taiwan, ROC 807
Durata Clinical Site
Taichung City, Taiwan, 40447
Durata Clinical Site
Taipai, Taiwan
Durata Study Site
Taipei, Taiwan, 10002
Durata Study Site
Yung Kang City, Taiwan, 71044
Ukraine
Durata Study Site
Cherkasy, Ukraine, 18009
Durata Study Site
Dnipropetrovsk, Ukraine, 49005
Durata Study Site
Donetsk, Ukraine, 83099
Durata Study Site
Ivano-Frankivsk, Ukraine, 76025
Durata Study Site
Ivano-Frankivsk, Ukraine, 76014
Durata Clinical Site
Ivano-Frankivsk, Ukraine, 76014
Durata Study Site
Kharkiv, Ukraine, 61058
Durata Study Site
Kyiv, Ukraine, 02666
Durata Clinical Site
Kyiv, Ukraine, 02666
Durata Study Site
Lviv, Ukraine, 79013
Durata Study Site
Lviv, Ukraine, 79059
Durata Study Site
Uzhhorod, Ukraine, 88000
Durata Study Site
Zaporizhia, Ukraine, 69032
Sponsors and Collaborators
Durata Therapeutics, Inc.
Investigators
Study Director: Michael Dunne, MD Durata Therapeutics, Inc.
  More Information

No publications provided by Durata Therapeutics, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Durata Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01431339     History of Changes
Other Study ID Numbers: DUR001-302
Study First Received: September 8, 2011
Results First Received: December 27, 2013
Last Updated: December 27, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Infection
Communicable Diseases
Wound Infection
Cellulitis
Wounds and Injuries
Skin Diseases, Infectious
Suppuration
Connective Tissue Diseases
Inflammation
Pathologic Processes
Vancomycin
Dalbavancin
Teicoplanin
Linezolid
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014